Drugs / ELS-M11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02057315 | Mar → Nov 2014 | migraine disorder | Achelios Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-09 | Achelios Therapeutics | Results Achelios to present TOPOFEN™ Results achelios.com ↗
Achelios Therapeutics (privately held, Chapel Hill, NC) today announced results from a Phase IIa placebo-controlled clinical trial in moderate and severe migraine sufferers treated with TOPOFEN™ (ELS-M11), the company’s proprietary topical anti-migraine therapy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-09 | Achelios Therapeutics | Achelios to present TOPOFEN™ Results achelios.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELS-M11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02057315 ↗ |
| Route | Topical | “for topical application” NCT02057315 ↗ |